Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Streptococcus pneumoniae remains a major contributor to childhood infections and deaths globally. In Cameroon, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in July 2011, using a 3-dose Expanded programme on immunization (EPI) schedule administered to infants at 6, 10 and 14 weeks of age. To evaluate PCV13 effects, we assessed pneumococcal nasopharyngeal colonization and serotype distribution among Cameroonian children after PCV13 introduction.
Methods: Nasopharyngeal (NP) swabs were collected from eligible children aged 24-36 months in two cross-sectional surveys conducted from March to July: in 2013 (PCV13-unvaccinated), and in 2015 (PCV13-vaccinated). Using a systematic World Health Organization (WHO) cluster coverage sampling technique in 40 communities, NP swabs collected were processed following WHO recommendations. Standard bacterial culture techniques were used for the isolation of S. pneumoniae from gentamicin-blood agar plates and identification using optochin susceptibility testing. Serotyping was performed using sequential multiplex polymerase chain reaction, supplemented with Quellung test.
Results: Among the PCV13-vaccinated children, overall pneumococcal carriage prevalence was 61.8% (426/689) and PCV13 vaccine-type carriage prevalence was 18.0% (123/689). Eleven out of the 13 vaccine serotypes were detected in the vaccinated children. The most common serotypes were 19F (4.5%, 31/689) and 15B/C (7.3%, 50/689).
Conclusion: In Cameroon, four years after infant vaccination nearly all of the PCV13-serotypes continued to circulate in the population. This suggests that the direct and indirect effects of the vaccination programme have not resulted in expected low levels of vaccine-type transmission. Continuous monitoring is needed to assess the long term effects of the PCV13 on nasopharyngeal carriage and disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2020.06.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Naturally acquired promoter variation influences Streptococcus pneumoniae infection outcomes.
Cell Host Microbe
August 2025
Division of Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. Electronic address:
Streptococcus pneumoniae colonizes human airways, where it acquires sugars from glycosylated mucins using glycoside hydrolases and sugar transport systems. This study identifies widespread nucleotide sequence variation in the promoter of a pneumococcal operon encoding a glycan scavenging system. We identify 78 promoter sequence patterns across 21,155 genomes, with variation clustered within a stretch of adenines, where mutations accumulate via strand slippage during DNA replication.
View Article and Find Full Text PDFThe significance of upper airway density of Streptococcus pneumoniae and respiratory viruses in the aetiology and severity of paediatric community-acquired pneumonia in Norway: An observational study.
J Microbiol Immunol Infect
August 2025
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Norway; Children's Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Objectives: Diagnosing paediatric Community-Acquired Pneumonia (CAP) is challenging due to the difficulty in obtaining lung specimens. Studies suggest that the upper-airway density of Streptococcus pneumoniae is related to the risk and severity of CAP. We studied the association between S.
View Article and Find Full Text PDFThe impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.
Vaccine
August 2025
Merck & Co., Inc., Rahway, NJ, USA. Electronic address:
To better inform pneumococcal immunization policies, ongoing surveillance for pneumococcal community-acquired pneumonia (CAP) is crucial. To estimate the serotype-specific CAP burden of pneumococcal disease following the introduction of a new 15-valent pneumococcal conjugate vaccine (PCV), V114, a 15-plex serotype-specific urine antigen detection (SSUAD) assay was developed as a tool for surveillance of Streptococcuspneumoniae serotypes. V114-017 (NCT03547167; EudraCT 2017-004915-38) was a phase 3 randomized controlled trial in which participants (18-49 years) received V114 or 13-valent PCV (PCV13; as an active comparator), followed 6 months later by 23-valent pneumococcal polysaccharide vaccine (PPSV23).
View Article and Find Full Text PDFInterplay between maternal Tdap and infant pneumococcal vaccination in shaping infant pneumococcal vaccine serotype carriage.
J Infect Dis
August 2025
Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium.
Background: Tetanus, Diphtheria and acellular Pertussis (Tdap) vaccination during pregnancy blunts the infant humoral immune response following primary immunization with pneumococcal conjugate vaccines (PCVs). While this effect typically resolves after the booster dose for most vaccine serotypes, its impact on nasopharyngeal carriage of pneumococcal vaccine serotypes remains unclear.
Methods: A total of 3,298 nasopharyngeal swabs were collected from infants aged 6-30 months attending daycare centers in Belgium between 2018 and 2022, along with data on maternal Tdap vaccination status (clinicaltrials.
Prediction of protein structural changes mediated by NS-SNPs in antibiotic resistance determinants in Streptococcus pneumoniae.
Arch Microbiol
August 2025
School of Electronics and Information, Hangzhou Dianzi University, Hangzhou, 310018, China.
Streptococcus pneumoniae (S. pneumoniae) is a gram-positive bacterium, which is a human pathogen that colonises the human nasopharyngeal region. The evolution of its resistance to many antibiotics has become a major clinical and public health problem.
View Article and Find Full Text PDF